Beam Therapeutics (BEAM) News Today $17.03 +0.20 (+1.19%) Closing price 04:00 PM EasternExtended Trading$17.05 +0.02 (+0.12%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BEAM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Voloridge Investment Management LLC Has $10.25 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)Voloridge Investment Management LLC reduced its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 10.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 413,409 shares of the company's stock after selling 50,253May 27 at 4:46 AM | marketbeat.comWoodline Partners LP Takes Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Woodline Partners LP purchased a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 282,120 shares of the company's stock, valuMay 26 at 4:37 AM | marketbeat.comDeutsche Bank AG Has $1.67 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Deutsche Bank AG grew its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 54.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 67,508 shares of the company's stock after purchasing an additional 23,871 shares duringMay 26 at 3:31 AM | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Buy" from AnalystsShares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been assigned an average rating of "Buy" from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, eleven have aMay 26 at 2:23 AM | marketbeat.comGoogle Beam Futuristic AI-Powered 3D Video Chats Are Coming This YearMay 23, 2025 | msn.comTwinbeech Capital LP Purchases 69,456 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Twinbeech Capital LP boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 119.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,664 shares of the company's stock after buyinMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Has $2.76 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Rafferty Asset Management LLC lowered its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 40.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,100 shares of the company's stock after selliMay 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 193,356 Beam Therapeutics Inc. (NASDAQ:BEAM)Point72 Asset Management L.P. bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 193,356 shares of the company's stock, valued aMay 22, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Tang Capital Management LLCTang Capital Management LLC lowered its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 70.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the company's stock after selling 120,00May 20, 2025 | marketbeat.comRaiffeisen Bank International AG Invests $1.26 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)Raiffeisen Bank International AG purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company's stock, valMay 19, 2025 | marketbeat.comPolar Asset Management Partners Inc. Acquires 187,455 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Polar Asset Management Partners Inc. increased its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 901.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,255 shares of the company's stock after acquiMay 18, 2025 | marketbeat.comHudson Bay Capital Management LP Sells 15,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Hudson Bay Capital Management LP cut its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 13.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the company's stock after selling 15May 16, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust CorpNorthern Trust Corp boosted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 7.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 740,506 shares of the company's stock after acquiring an additional 49,415 shares during the periMay 16, 2025 | marketbeat.comAlgert Global LLC Has $233,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Algert Global LLC reduced its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 78.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,378 shares of the company's stock after sellMay 15, 2025 | marketbeat.comBeam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 CongressMay 14, 2025 | globenewswire.comBeam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare ConferenceMay 13, 2025 | globenewswire.comHC Wainwright Issues Positive Forecast for BEAM EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for Beam Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($May 13, 2025 | marketbeat.comBeam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)May 12, 2025 | globenewswire.comLeerink Partnrs Issues Optimistic Forecast for BEAM EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for Beam Therapeutics in a note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will pMay 11, 2025 | marketbeat.comQ2 EPS Forecast for Beam Therapeutics Reduced by AnalystBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - William Blair cut their Q2 2025 earnings per share estimates for shares of Beam Therapeutics in a research note issued to investors on Tuesday, May 6th. William Blair analyst S. Corwin now expects that the company will post earnings of ($1.01)May 11, 2025 | marketbeat.comFarallon Capital Management LLC Purchases 31,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Farallon Capital Management LLC raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 0.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,239,123 shares of the company's stock after acquiring an aMay 11, 2025 | marketbeat.comCrestline Management LP Increases Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Crestline Management LP grew its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 261.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,969 shares of the company's stMay 11, 2025 | marketbeat.comTudor Investment Corp ET AL Sells 16,242 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Tudor Investment Corp ET AL trimmed its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 49.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,575 sharesMay 11, 2025 | marketbeat.comQ2 Earnings Estimate for Beam Therapeutics Issued By WedbushBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at Wedbush cut their Q2 2025 earnings estimates for Beam Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten now anticipates that the company will post earningMay 10, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Price Target Cut to $70.00 by Analysts at Wells Fargo & CompanyWells Fargo & Company lowered their target price on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday.May 9, 2025 | marketbeat.comBarclays Lowers Beam Therapeutics (NASDAQ:BEAM) Price Target to $25.00Barclays reduced their price target on shares of Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating for the company in a research report on Wednesday.May 9, 2025 | marketbeat.comIs Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth?May 9, 2025 | finance.yahoo.comRaymond James Financial Inc. Takes $703,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Raymond James Financial Inc. bought a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 28,328 shares of the company's stock, valued at approximately $703,000. Several otherMay 9, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Shares Down 6.8% on Disappointing EarningsBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.8% Following Weak EarningsMay 8, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Stock Holdings Raised by Casdin Capital LLCCasdin Capital LLC lifted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 61.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,250,000 shares of the company's stock after purchasing an additional 475,000 shares duringMay 8, 2025 | marketbeat.comDimensional Fund Advisors LP Has $38.16 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)Dimensional Fund Advisors LP lifted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 24.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,538,398 shares of the company's stock afMay 7, 2025 | marketbeat.comWhy Beam Therapeutics Stock Tanked on TuesdayMay 6, 2025 | fool.comBeam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 6, 2025 | globenewswire.comRenaissance Technologies LLC Makes New $568,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)Renaissance Technologies LLC purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 22,907 shares of the company's stock, valued at approxiMay 6, 2025 | marketbeat.comARCH Venture Management LLC Sells 294,521 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)ARCH Venture Management LLC lessened its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 6.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,540,132 shares of the company's stock after selling 2May 5, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Acquires New Shares in Beam Therapeutics Inc. (NASDAQ:BEAM)Susquehanna Fundamental Investments LLC acquired a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 52,725 shares of the company's stock, valMay 4, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Short Interest UpdateBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 18,830,000 shares, an increase of 27.7% from the March 31st total of 14,740,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the short-interest ratio is currently 8.9 days. Approximately 23.7% of the company's shares are sold short.May 4, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 266,834 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)Price T Rowe Associates Inc. MD raised its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 18.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,753,142 shares of the company's stock after purchasing anMay 2, 2025 | marketbeat.comBeam Therapeutics (BEAM) Projected to Post Quarterly Earnings on TuesdayBeam Therapeutics (NASDAQ:BEAM) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-beam-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comMarshall Wace LLP Buys Shares of 55,000 Beam Therapeutics Inc. (NASDAQ:BEAM)Marshall Wace LLP bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 55,000 shares of the company's stock, valued at approximately $1,364,000. Marshall Wace LLP owned 0.07% of BeMay 1, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Buy" from BrokeragesBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has received an average recommendation of "Buy" from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and tApril 30, 2025 | marketbeat.comPenn Medicine breaks ground for a $224 million proton beam cancer center in PhiladelphiaApril 29, 2025 | msn.comBarclays PLC Increases Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Barclays PLC boosted its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 51.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 278,019 shares of the company's stock after buying an additional 94,805 shares duringApril 27, 2025 | marketbeat.comWells Fargo & Company MN Has $3.17 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Wells Fargo & Company MN grew its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 17.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 128,002 shares of the company's stock after acquiApril 25, 2025 | marketbeat.comCathie Wood’s ARK Sells Adaptive Biotech, Buys Beam Therapeutics StockApril 24, 2025 | investing.comBeam Therapeutics Target of Unusually High Options Trading (NASDAQ:BEAM)Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the recipient of unusually large options trading on Tuesday. Traders acquired 10,060 put options on the stock. This is an increase of 1,089% compared to the typical volume of 846 put options.April 24, 2025 | marketbeat.comPatient with rare cancer first in US to be treated with highly accurate proton beam arc therapyApril 23, 2025 | msn.comBeam Therapeutics (NASDAQ:BEAM) Stock Price Up 5.5% - Still a Buy?Beam Therapeutics (NASDAQ:BEAM) Trading 5.5% Higher - Here's What HappenedApril 23, 2025 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Sees Significant Growth in Short InterestBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 14,740,000 shares, an increase of 21.2% from the March 15th total of 12,160,000 shares. Currently, 18.6% of the company's stock are short sold. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is presently 7.4 days.April 22, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Trading Up 9% - Time to Buy?Beam Therapeutics (NASDAQ:BEAM) Shares Up 9% - Here's WhyApril 16, 2025 | marketbeat.com Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Media Mentions By Week BEAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BEAM News Sentiment▼1.491.02▲Average Medical News Sentiment BEAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BEAM Articles This Week▼97▲BEAM Articles Average Week Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BPMC News BBIO News ELAN News VRNA News TLX News GRFS News TGTX News LEGN News NUVL News AXSM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BEAM) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BEAM Stock Free BEAM Stock Alerts